BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018
March 21, 2018 at 08:04 AM EDT
* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM
